AstraZeneca and Daiichi Sankyo have moved closer to securing a major European label expansion for Enhertu after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the antibody drug conjugate in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. The positive opinion, adopted on July 23, 2026, will now be considered by the European Commission before the combination can receive formal authorization across the European Union.
The proposed indication covers patients with tumors classified as HER2-positive through appropriate biomarker testing, including immunohistochemistry 3+ or in-situ hybridization-positive disease. The recommendation is based on the randomized Phase 3 DESTINY-Breast09 trial, which found that Enhertu plus pertuzumab substantially extended progression-free survival compared with the established combination of a taxane, trastuzumab and pertuzumab, commonly referred to as THP.
The regulatory development matters because first-line treatment for HER2-positive metastatic breast cancer has remained unusually stable for more than a decade. Enhertu has already changed treatment sequencing in previously treated breast cancer, but moving the medicine into the first-line setting would place it at the beginning of the metastatic treatment pathway, where treatment choices can influence several years of subsequent disease management.
It would also intensify scrutiny of the combination’s safety profile, particularly interstitial lung disease or pneumonitis, and raise practical questions about reimbursement, monitoring capacity and the continuing role of conventional taxane-containing therapy.
What exactly has the CHMP recommended for Enhertu in first-line metastatic breast cancer?
The CHMP recommended adding an indication under which Enhertu, or trastuzumab deruxtecan, would be used with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. Daiichi Sankyo Europe GmbH is the European marketing authorization holder, while Daiichi Sankyo and AstraZeneca jointly develop and commercialize Enhertu outside Japan under their global oncology collaboration.
The opinion is an important regulatory de-risking event, but it is not the same as European Commission authorization. The Commission must review the recommendation and formally change the medicine’s marketing authorization before the combination can be marketed under the expanded European label.
A favorable Commission decision would generally apply across European Union member states. It would not, however, guarantee immediate or uniform patient access. Individual countries and regional healthcare systems would still have to address pricing, health technology assessment, reimbursement and implementation.
Enhertu is already authorized in Europe for several HER2-defined cancer populations, including previously treated HER2-positive metastatic breast cancer and selected HER2-low or HER2-ultralow breast cancers. The proposed first-line indication is strategically different because it would move the drug ahead of the treatment sequence in which it originally established its commercial and clinical position.
Why could DESTINY-Breast09 disrupt the long-standing THP first-line treatment model?
DESTINY-Breast09 enrolled 1,157 adults with HER2-positive advanced or metastatic breast cancer who had not received chemotherapy or HER2-directed therapy for metastatic disease. Patients who had previously received treatment in the neoadjuvant or adjuvant setting could be included when their advanced disease developed more than six months after completing the earlier HER2-targeted therapy.
Participants were randomized among three groups. One received Enhertu with pertuzumab, another received Enhertu with a pertuzumab-matching placebo, and the control group received a taxane with trastuzumab and pertuzumab.
The disclosed interim analysis compared the Enhertu and pertuzumab combination with THP. Median progression-free survival assessed through blinded independent central review reached 40.7 months with Enhertu plus pertuzumab, compared with 26.9 months for THP.
That represented a 44% reduction in the risk of disease progression or death, with a hazard ratio of 0.56. The confidence interval ranged from 0.44 to 0.71, and the statistical result crossed the prespecified boundary for superiority.
The size of the progression-free survival difference is clinically relevant because it extends beyond a small numerical improvement. The reported median difference was approximately 13.8 months, potentially allowing eligible patients to remain on their initial metastatic treatment for considerably longer before radiographic progression or death.
Progression-free survival is not identical to overall survival, quality of life or freedom from cumulative toxicity. Nevertheless, delaying progression in metastatic breast cancer can affect the timing of subsequent therapies, exposure to additional treatment burden and the duration for which disease remains controlled under the initial regimen.
What do the response and duration data reveal beyond the headline progression result?
The confirmed objective response rate was 85.1% with Enhertu plus pertuzumab and 78.6% with THP. Complete responses were reported in 15.1% of patients receiving the Enhertu combination, compared with 8.5% in the control group.
Median duration of response reached 39.2 months with Enhertu plus pertuzumab, against 26.4 months with THP. The duration data therefore broadly reinforced the progression-free survival result by suggesting that responses were not only frequent but could also persist for an extended period.
The progression-free survival benefit was reported across prespecified subgroups, including patients categorized by hormone-receptor status, de novo versus recurrent metastatic disease and PIK3CA mutation status. Such consistency supports the breadth of the proposed indication, although subgroup analyses generally carry less statistical certainty than the primary comparison.
The study was also published in The New England Journal of Medicine, giving clinicians and regulators access to a peer-reviewed account rather than only a company announcement or conference abstract. That evidence maturity strengthens the regulatory case, although longer follow-up remains necessary to determine whether the progression advantage produces a clear overall survival benefit.
Overall survival data were not mature at the reported interim analysis. This does not undermine the successful progression-free survival endpoint, but it means the full effect on longevity remains unresolved, particularly in a disease area where patients may receive multiple effective subsequent therapies.
Why does the still-blinded Enhertu monotherapy arm remain an important unanswered question?
One of the most consequential unanswered questions is how much additional benefit pertuzumab contributes when combined with Enhertu. The trial included a third arm evaluating Enhertu with a pertuzumab-matching placebo, but data from that group remained blinded during the reported interim analysis.
The disclosed comparison therefore establishes that Enhertu plus pertuzumab outperformed THP. It does not yet establish whether the combination is meaningfully superior to Enhertu alone in the same first-line population.
That distinction could eventually matter to clinicians, payers and treatment guideline committees. Pertuzumab adds acquisition cost, infusion requirements and its own tolerability considerations. A future comparison showing limited incremental benefit could create pressure to reassess whether every eligible patient requires both HER2-directed agents.
Conversely, a clear advantage for the combination over Enhertu monotherapy would strengthen the biological and commercial rationale for maintaining dual HER2 blockade. Until that analysis becomes available, the regulatory decision is being made on the demonstrated superiority of the combination over the existing THP standard, rather than on proof that pertuzumab is indispensable to the new regimen.
How could the safety profile influence real-world adoption of Enhertu plus pertuzumab?
Grade 3 or higher adverse events occurred in 63.5% of patients receiving Enhertu plus pertuzumab and 62.3% of those receiving THP. The overall frequency of severe adverse events was therefore broadly similar, but the nature of the toxicity differed between the regimens.
The most commonly reported grade 3 or higher treatment-related events with Enhertu plus pertuzumab included neutropenia, hypokalemia and anemia. In the control group, prominent severe events included neutropenia, leukopenia and diarrhea.
Interstitial lung disease or pneumonitis remains the most clinically distinctive risk associated with trastuzumab deruxtecan. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of patients receiving Enhertu plus pertuzumab.
Most cases were grade 1 or grade 2, but two fatal grade 5 events were reported, representing 0.5% of patients in the combination arm. The THP group had a lower incidence, with events reported in 1% of patients and no disclosed high-grade cases in the published comparison.
These findings mean the combination cannot be assessed simply through the similar total percentages of grade 3 or higher adverse events. Oncology centers would require established pathways for recognizing respiratory symptoms, reviewing imaging, interrupting treatment and initiating appropriate management when interstitial lung disease is suspected.
Earlier use also changes the risk calculation. Patients entering first-line treatment may have received less metastatic therapy and could remain on treatment for several years. That increases the importance of cumulative tolerability, regular surveillance and prompt differentiation between drug-related pneumonitis, infection, cancer progression and other pulmonary conditions.
Does the new regimen remove conventional chemotherapy from first-line treatment?
Enhertu plus pertuzumab removes the need for a separately administered taxane in the experimental regimen, which could reduce some toxicities and treatment burdens commonly associated with taxane exposure. It should not, however, be described as a chemotherapy-free approach.
Enhertu is an antibody drug conjugate consisting of a HER2-targeting antibody linked to a topoisomerase I inhibitor payload. The antibody directs the conjugate toward HER2-expressing cells, after which the cytotoxic payload is released and interferes with DNA replication.
The regimen therefore represents a change in how cytotoxic treatment is delivered, rather than the elimination of cytotoxic therapy. The practical experience for patients may differ from conventional taxane-based therapy, but Enhertu carries its own adverse-event profile, including nausea, hematologic toxicity and interstitial lung disease.
Treatment is administered intravenously, generally once every three weeks. Pertuzumab also requires administration within an oncology setting, meaning the combination remains dependent on infusion capacity, specialist oversight and repeated monitoring.
What reimbursement and access hurdles will follow a European Commission decision?
A European Commission authorization would permit marketing under the expanded indication, but national reimbursement decisions would determine how rapidly the regimen reaches routine practice. Health technology assessment bodies are likely to examine the magnitude and durability of progression-free survival benefit, overall survival maturity, patient-reported outcomes, safety-management costs and the price of combining two branded HER2-directed medicines.
The comparator is an established regimen built around trastuzumab, pertuzumab and a taxane. As trastuzumab biosimilars and lower-cost taxanes are available, the economic difference between THP and the Enhertu combination could be substantial in some healthcare systems.
Payers may therefore focus on whether the longer period without progression offsets higher medicine costs through delayed subsequent therapy, fewer disease-related interventions or reduced use of separate taxane treatment. Those assumptions will require country-specific modeling and may evolve as overall survival and quality-of-life data mature.
Biomarker identification should be comparatively familiar because HER2 testing is already embedded in breast cancer practice. Access differences could nevertheless emerge from national pricing negotiations, hospital budgets and the ability of treatment centers to support intensive toxicity monitoring.
How does the CHMP opinion affect AstraZeneca and Daiichi Sankyo commercially?
First-line use could materially expand the duration and number of patients exposed to Enhertu. A medicine prescribed at the beginning of metastatic treatment may remain in use longer than one reserved for later lines, particularly when median progression-free survival exceeds three years.
The recommendation also validates the broader strategy of moving antibody drug conjugates into earlier disease settings. Daiichi Sankyo and AstraZeneca are testing Enhertu across multiple stages of breast cancer and in several HER2-defined solid tumors, creating the possibility of a wider franchise built around tumor biology rather than one narrow treatment line.
The immediate market reaction was not a clean measure of the recommendation’s value. AstraZeneca shares closed in London on July 24 at 12,670 pence, down 0.14% for the session, while Daiichi Sankyo shares rose 1.62% in Tokyo to 2,799.5 yen.
Those movements coincided with the regulatory update but do not establish that it caused either change. AstraZeneca was also facing broader investor scrutiny after a separate late-stage cardiovascular trial setback, leaving sentiment influenced by multiple pipeline developments rather than the Enhertu opinion alone.
For both companies, the recommendation is best viewed as a regulatory de-risking event and a potential long-term commercial expansion. The financial impact will depend on the timing of Commission authorization, reimbursement decisions, treatment uptake and the contribution of first-line sales relative to Enhertu’s already broadening portfolio.
What will determine whether Enhertu becomes Europe’s preferred first-line HER2 regimen?
The next formal milestone is the European Commission’s decision on the CHMP recommendation. Assuming authorization is granted, attention will shift quickly to the final product information, national pricing negotiations, reimbursement assessments and incorporation into European clinical guidelines.
Clinicians will also watch for more mature overall survival data and the eventual disclosure of results from the Enhertu monotherapy arm. Those findings could clarify both the long-term value of the combination and the specific contribution made by pertuzumab.
Real-world pharmacovigilance will be equally important. The ability of hospitals to detect and manage interstitial lung disease early could influence confidence in using the regimen across a broader first-line population.
DESTINY-Breast09 has already demonstrated a substantial progression-free survival advantage over THP and has given European regulators sufficient evidence to recommend the new indication. The remaining test is whether the combination can translate that trial advantage into durable survival outcomes, manageable toxicity and economically sustainable access across Europe’s fragmented healthcare systems.
